Skip to main content
Premium Trial:

Request an Annual Quote

NovellusDx Inks Japan Distribution Deal for Cancer Treatment Response Assay

NEW YORK (GenomeWeb) — NovellusDx said today that it has signed a deal with Primetech for the distribution of its functional annotation for cancer treatment (FACT) assay in Japan.

The next-generation sequencing-based FACT assay is designed to test the functional effects of variants of unknown significance in reponse to various cancer treatments to predict clinical results.

Under the terms of the deal, Tokyo-based Primetech will be the exclusive dealer for the assay for the preclinical market in Japan, providing all related sales, marketing, research, and technical support in the region.

Additional terms were not disclosed.

Earlier this year, Jerusalem-based NovellusDx partnered with Centre Léon-Bérard to evaluate the accuracy of the FACT assay in predicting treatment responses in cancer patients. The company also recently raised $6 million in equity financing.